- Home
- ACAD
as 03-28-2025 4:00pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.8B | IPO Year: | 2004 |
| Target Price: | $24.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.15 - $20.68 | Next Earning Date: | 05-07-2025 |
| Revenue: | $957,797,000 | Revenue Growth: | 31.85% |
| Revenue Growth (this year): | 13.07% | Revenue Growth (next year): | 9.97% |
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Mar 24 '25 | Sell | $17.05 | 1,095 | $18,669.75 | 21,275 | |
| GAROFALO ELIZABETH A. | ACAD | Director | Mar 5 '25 | Sell | $18.23 | 4,919 | $89,673.37 | 17,595 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Feb 23 '25 | Sell | $19.96 | 475 | $9,481.00 | 21,275 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Feb 23 '25 | Sell | $19.96 | 773 | $15,429.08 | 53,882 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
ACAD: What does Argus have to say about ACAD?
Insider Monkey
4 days ago
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts
Insider Monkey
12 days ago
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?
Business Wire
15 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
16 days ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire
24 days ago
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Zacks
24 days ago
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
Argus Research
25 days ago
ACAD: Lowering target price to $19.00
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.